English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi 当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
インデックス付き
- Google スカラー
- パブロン
- ICMJE
役立つリンク
オープンアクセスジャーナル
このページをシェアする
抽象的な
Omalizumab's Effectiveness and Safety in Treating Adult Patients with Exercise-Induced Anaphylaxis caused by Wheat: decrease of in Vitro Basophil Activation and Allergic Reactivity to Wheat
Zoe Gilbert
Anaphylactic shock usually occurs in people with wheat-dependent exercise-induced anaphylaxis (WDEIA), hence avoiding wheat products is advised. For adult patients with WDEIA, our goal was to assess the effectiveness and safety of long-term omalizumab treatment. 20 adult WDEIA patients were enrolled in this phase 2, multicenter, single-arm experiment (UMIN 000019250). Every patient received 150-600 mg of omalizumab subcutaneously, and during the administration period (0-48 weeks) and observation period, assessments (basophil activation and blood testing) were carried out at regular intervals (48–68 weeks). The proportion of patients who reached a basophil activation rate of less than 10% with fractionated wheat preparations served as the primary endpoint, while the proportion of patients who experienced no allergic reactions after consuming wheat products served as the secondary endpoint.